Is the iShares Healthcare ETF or the Invesco Nasdaq Biotech ETF the Better Bet for Investors in 2026? One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppression through 48 weeks.
3 Market-Beating Stocks with Solid Fundamentals The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today Gilead Sciences (
NASDAQ:GILD ) has outperformed the market over the past 20 years by 2.19% on an annualized basis producing an average annual return of 11.43%. Currently, Gilead Sciences has a market capitalization of
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now? BBH offers concentrated exposure to biotech, while IHE provides higher income with lower volatility by focusing on established drugmakers.
IXJ vs. IBBQ: Global Healthcare vs. Biotech -- Which ETF Is the Better Buy? IBBQ's concentrated biotech play has delivered a higher one-year return, while IXJ'S diversified global healthcare fund has been much less volatile.
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move. Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.
Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026? RSPH offers 60 diversified holdings with lower volatility, while BBH concentrates on 25 biotech leaders with stronger recent returns.
Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1 Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.
Which is the Better Choice for Healthcare Investors? IYH or BBH? BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.
2 Recession-Resistant Dividend Stocks to Buy and Hold You don't need to predict a recession to prepare your portfolio. These two stocks can help.
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.
Which Healthcare ETF Is the Better Buy: Invesco's IBBQ or State Street's XPH? IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility.
BBH vs. XPH: Which Healthcare ETF Is Better for Beginners? Broader diversification and lower volatility set these healthcare ETFs apart, with each fund targeting a distinct segment of the industry.
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential.
FHLC vs. BBH: Which Healthcare ETF Is the Better Buy? Compare fees, diversification, and risk between these two leading healthcare ETFs.
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today Gilead Sciences (
NASDAQ:GILD ) has outperformed the market over the past 20 years by 2.07% on an annualized basis producing an average annual return of 11.3%. Currently, Gilead Sciences has a market capitalization of
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.
